ABSTRACT
INTRODUCTION
Acute eosinophilic pneumonia (AEP) is a clinicopathological disease characterized by acute respiratory failure and massive pulmonary infiltration of eosinophils. 1 Although eosinophils recruited from the peripheral circulation into the alveolar spaces play central roles in the pathogenesis of AEP, the exact mechanism of eosinophil accumulation remains to be elucidated.
The processes of eosinophil accumulation into inflammation sites are complex and are regulated by several factors including adhesion molecules expressed on eosinophils and endothelial cells, and pro-inflammatory molecules including lipid mediators and cytokines/ chemokines. 2 To date, constitutive and/or inducible expression of CC chemokine receptor (CCR) 1, CCR3, CXC chemokine receptor (CXCR) 1, CXCR2, CXCR3 and CXCR4 in human peripheral blood eosinophils has been reported. [3] [4] [5] [6] [7] Of these receptors, CCR3 is highly
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and constitutively expressed on eosinophils. 8 CCR3 ligands such as eotaxin, eotaxin-2, eotaxin-3, regulated upon activation, normal T cell expressed and secreted (RANTES), monocyte chemotactic protein (MCP)-2, MCP-3 and MCP-4 induce eosinophil recruitment in allergic inflammation. 5, 9 Katoh et al. reported that the concentration of eotaxin is increased in the bronchoalveolar lavage fluid (BALF) of eosinophilic pneumonia. 10 Tateno et al. also reported that eotaxin was elevated in the BALF of chronic eosinophilic pneumonia. 11 Therefore, CCR3 ligands including eotaxin might be involved in the pathogenesis of AEP.
Other chemokines may also be implicated in the eosinophil accumulation in AEP. For example, Katoh et al. reported that CXCR3 ligands such as interferon gamma (IFN-γ)-inducible protein of 10 kDa (IP-10) and monokine induced by IFN-γ (Mig) and CXCR3-expressing eosinophils were elevated in the BALF of chronic eosinophilic pneumonia. 12 Eosinophils express CXCR3 and CXCR3 ligands directly induce eosinophil migration. 7 Furthermore, we have reported that CXCR3 ligands upregulate effector functions of eosinophils such as adhesion, superoxide anion generation, eosinophil-derived neurotoxin release and cytokine/ chemokine production. 13 Therefore, CXCR3 ligands could play some role in the development of AEP.
Eosinophil growth factors, including interleukin (IL)-5, may also contribute to eosinophil accumulation via their survival-enhancing effect on the cells.
14 It has been reported that IL-5, but not granulocyte-macrophage colony stimulating factor (GM-CSF), is increased in the BALF of AEP. [15] [16] [17] Moreover, lipid mediators such as leukotriene (LT) B 4 , cysLTs and platelet activating factor (PAF) may be involved in the development of AEP. LTB 4 , LTD 4 and PAF are potent chemoattractants for eosinophils, [18] [19] [20] and expression of both LTB 4 and cysLTs is upregulated in eosinophilic pneumonia. 21 The objective of this study was to evaluate the mechanisms of eosinophil accumulation in the alveolar spaces in AEP. In the present study, we investigated whether BALF obtained from patients with AEP (AEP-BALF) induces blood eosinophil transmigration across endothelial cells.
METHODS

Patients
Eight patients with AEP, eight with sarcoidosis who exhibited bilateral hilar lymphadenopathy but not interstitial lung disease and eight with hypersensitivity pneumonitis (HP) (four with summer-type 22 and another four with unknown aetiologies) were included in this study (Table S1 , Supplementary Information). The diagnosis of AEP, as described by Allen et al. 1 or Cottin and Cordier, 23 was made by acute onset of respiratory failure, diffuse pulmonary infiltrates on chest X-ray films and increased number of eosinophils in BALF (more than 25% of the total cells). The characteristics of AEP are presented in Table S2 (Supplementary Information). We assumed that AEP was related to smoking if patients started smoking less than 1 month before AEP onset and they did not have any identifiable cause of AEP. 24, 25 This study was approved by the Institutional Review Board of Saitama Medical University Hospital, and written informed consent was obtained from the patients.
Bronchoalveolar lavage fluid
A bronchofiberscope (Olympus, Tokyo, Japan) was wedged into a subsegmental bronchus of either the right middle lobe or the left lingula, and lavage was performed by a combination of infusion of 50 mL saline and subsequent gentle aspiration, repeated four times. Fluid recovered from the third and fourth lavages was used as BALF. Cytocentrifuged slides were stained with May-Giemsa to determine cell differentials. The supernatants of BALF were immediately stored at −80 C until analysis. 
ELISA for cytokines/chemokines
Eosinophil transendothelial migration
Eosinophils were isolated by negative immunomagnetic bead selection as previously described. 13, [26] [27] [28] [29] [30] [31] Human pulmonary microvascular endothelial cells (HPMECs) were prepared as previously described. [26] [27] [28] Eosinophil transendothelial migration was examined using a previously described method. [26] [27] [28] [29] Details are described in Appendix S1 (Supplementary Information).
Statistical analysis
Data are presented as means AE SEM. For statistical analyses, Student's t-test was used for paired comparisons, and a repeated-measures analysis of variance (ANOVA) with repeated measures and Scheffe constants were used for comparison of more than two variables to determine significance. Values of P < 0.05 were considered statistically significant.
RESULTS
Eosinophil transendothelial migration induced by BALF
In the initial series of experiments, eosinophil transendothelial migration was examined in the presence or absence of BALF from AEP, sarcoidosis or HP. AEP-BALF significantly induced eosinophil migration compared with BALF from sarcoidosis, HP or control (Fig. 1A) . To evaluate eosinophil adhesion molecule(s) involved in this enhanced transendothelial migration, eosinophils were incubated with anti-β 2 integrin monoclonal antibody (mAb), anti-α 4 integrin mAb or isotypematched control mouse immunoglobulin (Ig) G1, and a migration assay was then performed. Anti-β 2 integrin mAb, but not anti-α 4 integrin mAb, almost completely blocked the AEP-BALF-enhanced migration (Fig. 1B) . In order to confirm the lack of a role of eosinophil α 4 integrins in this migration, we evaluated whether endothelial expression of vascular cell adhesion molecule (VCAM)-1 (a counter ligand of α 4 integrins) modified the AEP-BALF-induced eosinophil transendothelial migration by comparing the migration of the eosinophils through resting and IL-4 + TNF-α-stimulated VCAM-1-expressing HPMECs. 26 Eosinophil migration through resting and stimulated HPMECs was similar, and there was no significant difference in migration between these two experimental conditions (%migration: 17.8 AE 3.1 through resting vs 19.9 AE 2.7 through IL-4 + TNF-α-stimulated HPMECs; not significant).
Role of CCR3 ligands in the AEP-BALFinduced eosinophil transendothelial migration
To evaluate the involvement of CCR3 ligands in the AEP-BALF-induced eosinophil transendothelial migration, the concentrations of CCR3 ligands in the AEP-BALF were measured. Higher levels of eotaxin were detected in the BALF from two of the eight AEP patients but there were no significant differences between the groups ( Fig. 2A) . The concentration of eotaxin-2, but not of eotaxin-3, was significantly increased in the AEP-BALF (Fig. 2B ,C), suggesting that eotaxin-2 may be involved in the pathogenesis of AEP. The concentration of RANTES was significantly higher in the BALF of HP, but was not significantly elevated in the AEP-BALF (Fig. 2D ). MCP-2 and MCP-3 levels were not upregulated in the AEP-BALF (Fig. 2E,F ). In contrast, MCP-4 was significantly increased in the AEP-BALF (Fig. 2G ), suggesting that MCP-4 may also play a role in the pathogenesis of AEP. Next, the effect of a neutralizing anti-CCR3 mAb on eosinophil transendothelial migration was examined. Treatment with an anti-CCR3 mAb (3 μg/mL) that abolished eosinophil migration induced by 30 nmol/L eotaxin (data not shown) inhibited the AEP-BALF-induced eosinophil migration (Fig. 2H ). Furthermore, treatment with an anti-MCP-4 mAb (3 μg/mL), which abolished eosinophil migration induced by 10 nmol/L MCP-4 (data not shown), also inhibited the AEP-BALF-induced eosinophil migration (Fig. 2I ). These results suggested that CCR3 ligands including eotaxin-2 and MCP-4 play role(s) in the accumulation of eosinophils in AEP.
Role of CXCR3 ligands in the AEP-BALFinduced eosinophil transendothelial migration
The concentrations of IP-10, Mig and I-TAC were all elevated in the BALF of HP (Fig. 3A-C) but were not significantly increased in the AEP-BALF (Fig. 3A-C) . Treatment with an anti-CXCR3 mAb (3 μg/mL), which has been shown to abolish the adhesion of eosinophils to intercellular adhesion molecule-1 induced by 100 nmol/L IP-10, 13 did not modify the AEP-BALF-induced migration of eosinophils (Fig. 3D) . These results suggested that CXCR3 ligands are not involved in the eosinophil transendothelial migration in AEP.
Role of CCR4 ligands in the AEP-BALFinduced eosinophil transendothelial migration
As the concentrations of CCR4 ligands are increased in the BALF and serum of AEP patients, 32 Eosinophil accumulation in AEP transendothelial migration of eosinophils was evaluated. A significant increase in the concentrations of TARC and MDC in the AEP-BALF was confirmed (Fig. 4A,B) . However, treatment with a CCR4 antagonist (1 μmol/L), which suppresses the chemotaxis of human CCR4-expressing cells, 34 did not modify the AEP-BALF-induced eosinophil transendothelial migration (Fig. 4C) . These results suggested that, although CCR4 ligands are upregulated in the AEP-BALF, these ligands do not contribute to the eosinophil transendothelial migration in AEP.
Role of eosinophil growth factors in the AEP-BALF-induced eosinophil transendothelial migration
The concentration of IL-5 was significantly higher in the AEP-BALF compared with that in the BALF of sarcoidosis or HP (Fig. S1, Supplementary Information) . GM-CSF was not upregulated in the AEP-BALF (Fig. S1 , Supplementary Information). Treatment with an anti-IL-5 mAb (3 μg/mL), which completely abolished the eosinophil adhesion to resting HPMECs that was induced by 100 pmol/L recombinant human-IL-5 (data not shown), did not modify the AEP-BALF-induced eosinophil transendothelial migration (Fig. S1 , Supplementary Information. These results suggested that, although IL-5 is upregulated in the AEP-BALF, it does not contribute to the transendothelial migration of eosinophils in AEP.
Role of lipid mediators in the AEP-BALFinduced eosinophil transendothelial migration
Finally, the involvement of lipid mediators in the AEP-BALF-induced eosinophil transendothelial migration were measured using ELISA. *P < 0.05 and **P < 0.01 versus other conditions. (H,I) The effect of anti-CCR3 mAb and anti-MCP-4 mAb on the AEP-BALF-induced eosinophil transmigration, respectively. Eosinophils were incubated with, respectively, anti-CCR3 mAb (3 μg/mL) and anti-MCP-4 mAb (3 μg/mL) or control IgG for 20 min, and transendothelial migration of the eosinophils was then examined. Data represent means AE standard error of the mean from five experiments. *P < 0.05 versus control IgG, **P < 0.01 versus control IgG. AEP, acute eosinophilic pneumonia; BALF, bronchoalveolar lavage fluid; CCR, CC chemokine receptor; HP, hypersensitivity pneumonitis; MCP, monocyte chemotactic protein; RANTES, regulated upon activation, normal T cell expressed and secreted.
was evaluated. The concentration of LTB 4 was significantly increased in the AEP-BALF (Fig. 5A) . Furthermore, treatment with BIIL260 (10 μmol/L), an LTB 4 receptor antagonist that abolished eosinophil migration induced by 1 μmol/L LTB 4 (data not shown), suppressed the AEP-BALF-induced eosinophil transendothelial migration (Fig. 5B) . On the other hand, treatment with montelukast (10 μmol/L), an LT receptor antagonist (LTRA) that abolished eosinophil migration induced by 1 μmol/L LTD 4 (data not shown), did not significantly suppress this eosinophil transendothelial migration (Fig. 5C) . Similarly, treatment with WEB2086 (20 μmol/L), a PAF receptor antagonist that abolished the eosinophil migration across resting HPMECs induced by 1 μmol/L PAF (data not shown), did not modify the AEP-BALF-induced eosinophil transendothelial migration (Fig. 5D ). These findings suggested that LTB 4 could be a partial contributing factor to the AEP-BALF-induced eosinophil transmigration. 
DISCUSSION
This study demonstrated that BALF from AEP, but not BALF from sarcoidosis or HP, specifically induced the transendothelial migration of peripheral blood eosinophils obtained from healthy donors. This induced migration appeared to be dependent on the β 2 integrin pathway. The present data also suggested an inhibitory effect of anti-CCR3 mAb or an LTB 4 receptor antagonist on the AEP-BALF-induced eosinophil transmigration. However, as these suppressive effects on eosinophil transendothelial transmigration were partial, chemoattractant(s) other than CCR3 ligands or LTB 4 might also be involved in eosinophil recruitment in AEP.
CCR3 is a major chemokine receptor of eosinophils. 8 It has been shown that pretreatment of eosinophils with anti-CCR3 mAb abrogates their chemotactic response to CCR3 ligands such as eotaxin, RANTES, MCP-2, MCP-3 and MCP-4 in vitro. 5, 9 Among CCR3 ligands, eotaxin is a potent chemoattractant that induces in vitro eosinophil migration across endothelial cells. 35 Katoh et al. reported that the level of eotaxin was elevated in the BALF of eosinophilic pneumonia, 10 although it is not clear whether the patients were acute or chronic. In the present study, we demonstrated some role of CCR3-activating chemokines in the transendothelial migration of eosinophils in AEP. In this study, the concentrations of eotaxin-2 and MCP-4 were increased in the AEP-BALF. Eotaxin-2 is a potent chemoattractant for eosinophils through CCR3 binding. 36, 37 The expression of eotaxin-2 is upregulated in airway epithelial cells from asthmatic patients and is highest in severe asthma patients. 38 MCP-4, which is mainly produced by epithelial cells and mononuclear cells including lymphocytes, is also a potent chemoattractant for eosinophils and induces a calcium flux in CCR3-positive cells. 39, 40 Complete cross-desensitization was observed between eotaxin-2, eotaxin and MCP-4 confirming activation via CCR3. 36, 37 We found that treatment with an anti-MCP-4 mAb suppressed the AEP-BALF-induced eosinophil transendothelial migration. Therefore, eotaxin-2 and MCP-4 might be specifically important for induction of transendothelial migration of eosinophils in AEP.
CXCR3 is expressed on eosinophils, and CXCR3 ligands directly upregulate the effector functions of eosinophils. 7, 13 In this study, CXCR3 ligands were not significantly upregulated in the AEP-BALF. Furthermore, treatment with an anti-CXCR3 mAb did not suppress the transendothelial migration of eosinophils, suggesting that CXCR3 ligands play a negligible role in the eosinophil transendothelial migration in AEP. However, there is evidence to suggest that expression of chemokine receptors on eosinophils differed between eosinophils from peripheral blood and those from BALF. 12, 41, 42 For example, Liu et al. reported that airway eosinophils showed increased CXCR3 and decreased CCR3 expression compared with eosinophils in peripheral blood. 41 Katoh et al. reported that there were higher percentages of CXCR3-expressing eosinophils in BALF than in peripheral blood. 12 These findings strongly indicated that eosinophils in airways express more CXCR3 and less CCR3 compared with eosinophils in peripheral blood. Therefore, especially in airways, CXCR3 ligands might play important roles in the activation and migration of eosinophils. Further study using airway eosinophils from AEP patients is required to clarify the actual role of CXCR3 ligands in eosinophil transendothelial migration in AEP.
The concentrations of CCR4 ligands such as TARC and MDC have been reported to be increased in the BALF and serum of AEP patients. 32, 33 Furthermore, increased TARC is detected in the peripheral circulation of AEP patients, even when blood eosinophilia is absent, 43 suggesting that an increase in TARC would precede eosinophilic infiltration. CCR4 is preferentially expressed on T helper (Th) 2 cells, but not on eosinophils, and thus it is assumed that CCR4 ligands could induce eosinophilic inflammation through activation of Th2 cells. In the present study, a CCR4 antagonist did not modify the AEP-BALF-induced eosinophil transendothelial migration. This finding suggested that, although CCR4 ligands are upregulated in the AEP-BALF, they do not directly induce eosinophil accumulation in AEP. However, Liu et al. reported that the expression of CCR4 could be induced in airway eosinophils after activation. 41 Therefore, especially in airways, CCR4 ligands might play a direct role in the activation and/or migration of eosinophils in a manner similar to CXCR3 ligands. Furthermore, some reports have suggested that CCR4 ligands can induce the migration of eosinophils in a CCR4-independent manner, probably through another yet-to-be-defined receptor. 44 This mechanism might be involved in eosinophil transendothelial migration in AEP, and this possibility should be investigated.
IL-5 is a well-recognized mediator of eosinophilic inflammation. 8 The in vitro effects of IL-5 on eosinophils include prolongation of eosinophil survival and modification of their functions. 14 The level of IL-5 was elevated in the BALF of AEP, which is consistent with previous reports, [15] [16] [17] suggesting that IL-5 might be involved in the pathogenesis of AEP. However, in the present study, anti-IL-5 mAb did not modify the AEP-BALF-induced eosinophil transendothelial migration. This finding suggests the lack of a role for IL-5 in the chemotactic movement of cells in AEP. Rather, IL-5 is likely to be involved in both the enhanced survival and the manifestation of effector functions of eosinophils in the lung parenchyma in AEP.
Lipid mediators may also be involved in the AEP-BALF-induced eosinophil transmigration. In the present study, LTB 4 was upregulated in the AEP-BALF and the AEP-BALF-induced transmigration of eosinophils was suppressed by an LTB 4 receptor antagonist. Therefore, LTB 4 could play an important role in the enhanced AEP-BALF-induced eosinophil transmigration. Other possible candidate lipid mediators may include eosinophil chemoattractants such as prostaglandin D 2 45 and 5-oxo-eicosanoids. 46 The concentrations of eotaxin-2 or MCP-4 in BALF were higher in smoking-related AEP as compared with other AEPs (Appendix S2 and Figure S2 ). Furthermore, BALF from smoking-related AEP induced greater eosinophil migration than BALF from other AEPs (data not shown). However, Nureki et al. reported that, if BAL was performed 6 days after onset of AEP, cytokine concentrations were much lower than those measured at an earlier examination. 47 Therefore, high concentrations of cytokines/chemokines in smoking-related AEP may be associated with shorter duration from onset to BAL, irrespective of cause (smoking). Furthermore, the small sample sizes in this study make it difficult to clarify the differences in cytokine/chemokine profiles between smoking-related AEP and idiopathic AEP.
One limitation of this study is that we used BALF from patients with sarcoidosis, but not from healthy volunteers, or saline as a control. However, in a preliminary experiment, eosinophil transendothelial migration induced by the BALF from patients without lung disease was negligible and was not different from that induced by the BALF from sarcoidosis (data not shown). Furthermore, cytokine/chemokine concentrations in the BALF of sarcoidosis were lower than those of HP or other interstitial pneumonia, and most of them were below the detection limit. Another limitation is that inhibition of eosinophil transendothelial migration by an LTB 4 antagonist was weak. Furthermore, there is little information available regarding the selectivity of BIIL260. Birke et al. reported that BIIL260 has high affinity for the LTB 4 receptor on isolated human neutrophil cell membranes, having a Ki value of 1.7 nmol/L. 48 They also performed receptor binding assays of 27 different human non-LTB 4 receptors and their specific ligands, and found that no relevant binding of BIIL260 was observed, suggesting high selectivity of this drug. 48 In preliminary experiments, we found that treatment with BIIL260 (10 μmol/L) abolished eosinophil migration induced by 1 μmol/L LTB 4 , but not that induced by 30 nmol/L eotaxin (data not shown). Furthermore, we previously used the same concentrations of an LTB 4 antagonist to examine the mechanisms by which IL-8-stimulated neutrophils 31 or lipopolysaccharide-stimulated neutrophils 49 enhanced eosinophil trans-basement membrane migration. However, we could not completely exclude the possibility of nonspecific effect of these antagonists.
In conclusion, the BALF from patients with AEP induced eosinophil transmigration across pulmonary endothelial cells. CCR3 ligands including eotaxin-2 and MCP-4, as well as LTB 4 may play roles in the accumulation of eosinophils in AEP. 
